Published in Int J Environ Res Public Health on May 13, 2015
Stenotrophomonas maltophilia: An Emerging Pathogen in Paediatric Population. J Clin Diagn Res (2017) 0.75
Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol (1995) 88.05
DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev (1997) 9.69
DNA gyrase: structure and function. Crit Rev Biochem Mol Biol (1991) 5.25
Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin Microbiol Rev (2012) 4.39
Emerging plasmid-mediated quinolone resistance associated with the qnr gene in Klebsiella pneumoniae clinical isolates in the United States. Antimicrob Agents Chemother (2004) 3.54
Efflux-mediated drug resistance in bacteria: an update. Drugs (2009) 3.18
Stenotrophomonas, a new bacterial genus for Xanthomonas maltophilia (Hugh 1980) Swings et al. 1983. Int J Syst Bacteriol (1993) 3.16
DNA gyrase and topoisomerase IV on the bacterial chromosome: quinolone-induced DNA cleavage. J Mol Biol (1996) 3.08
DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance. Proc Natl Acad Sci U S A (1997) 2.99
Multidrug efflux pumps and antimicrobial resistance in Pseudomonas aeruginosa and related organisms. J Mol Microbiol Biotechnol (2001) 2.97
Stenotrophomonas maltophilia: an emerging opportunist human pathogen. Lancet Infect Dis (2009) 2.61
gyrA mutations associated with fluoroquinolone resistance in eight species of Enterobacteriaceae. Antimicrob Agents Chemother (1998) 2.35
Cloning and characterization of SmeDEF, a novel multidrug efflux pump from Stenotrophomonas maltophilia. Antimicrob Agents Chemother (2000) 2.17
Antimicrobial therapy for Stenotrophomonas maltophilia infections. Eur J Clin Microbiol Infect Dis (2007) 2.01
Efflux pumps as antimicrobial resistance mechanisms. Ann Med (2007) 1.99
Therapeutic options for Stenotrophomonas maltophilia infections beyond co-trimoxazole: a systematic review. J Antimicrob Chemother (2008) 1.73
SmeC, an outer membrane multidrug efflux protein of Stenotrophomonas maltophilia. Antimicrob Agents Chemother (2002) 1.60
Expression of multidrug efflux pump SmeDEF by clinical isolates of Stenotrophomonas maltophilia. Antimicrob Agents Chemother (2001) 1.53
The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in-vitro activities of ciprofloxacin, sparfloxacin and moxifloxacin against clinical isolates of Staphylococcus aureus. J Antimicrob Chemother (1998) 1.48
SmeDEF multidrug efflux pump contributes to intrinsic multidrug resistance in Stenotrophomonas maltophilia. Antimicrob Agents Chemother (2001) 1.45
Pulsed field gel electrophoresis: a review of application and interpretation in the molecular epidemiology of infectious disease. Infect Genet Evol (2010) 1.30
Stenotrophomonas maltophilia: emergence of multidrug-resistant strains during therapy and in an in vitro pharmacodynamic chamber model. Antimicrob Agents Chemother (1996) 1.28
The effect of reserpine, a modulator of multidrug efflux pumps, on the in vitro activity of tetracycline against clinical isolates of methicillin resistant Staphylococcus aureus (MRSA) possessing the tet(K) determinant. Phytother Res (2000) 1.24
SmeDEF-mediated antimicrobial drug resistance in Stenotrophomonas maltophilia clinical isolates having defined phylogenetic relationships. J Antimicrob Chemother (2006) 1.22
Smqnr, a new chromosome-carried quinolone resistance gene in Stenotrophomonas maltophilia. Antimicrob Agents Chemother (2008) 1.18
Prevalence of the oqxAB gene complex in Klebsiella pneumoniae and Escherichia coli clinical isolates. J Antimicrob Chemother (2012) 1.16
Role of efflux pumps in the antibiotic resistance of bacteria embedded in a biofilm. Virulence (2013) 1.15
Mechanism of action of and resistance to quinolones. Pharmacotherapy (2001) 1.10
SmQnr contributes to intrinsic resistance to quinolones in Stenotrophomonas maltophilia. Antimicrob Agents Chemother (2009) 1.09
DNA gyrase and topoisomerase IV mutations associated with fluoroquinolone resistance in Proteus mirabilis. Antimicrob Agents Chemother (2002) 1.08
Stenotrophomonas maltophilia: emerging disease patterns and challenges for treatment. Expert Rev Anti Infect Ther (2011) 1.07
Topoisomerase II and IV quinolone resistance-determining regions in Stenotrophomonas maltophilia clinical isolates with different levels of quinolone susceptibility. Antimicrob Agents Chemother (2002) 1.04
Contribution of integrons, and SmeABC and SmeDEF efflux pumps to multidrug resistance in clinical isolates of Stenotrophomonas maltophilia. J Antimicrob Chemother (2004) 1.01
New treatments for emerging cystic fibrosis pathogens other than Pseudomonas. Curr Pharm Des (2012) 1.00
Novel variants of the Smqnr family of quinolone resistance genes in clinical isolates of Stenotrophomonas maltophilia. J Antimicrob Chemother (2010) 0.95
Mutations in gyrA and parC QRDRs are not relevant for quinolone resistance in epidemiological unrelated Stenotrophomonas maltophilia clinical isolates. Microb Drug Resist (2002) 0.94
Coastal seawater bacteria harbor a large reservoir of plasmid-mediated quinolone resistance determinants in Jiaozhou Bay, China. Microb Ecol (2012) 0.90
Risk factors for mortality and clinical implications of catheter-related infections in patients with bacteraemia caused by Stenotrophomonas maltophilia. Int J Antimicrob Agents (2008) 0.90
Characterization of plasmid-mediated quinolone resistance (PMQR) genes in extended-spectrum β-lactamase-producing Enterobacteriaceae pediatric clinical isolates in Mexico. PLoS One (2013) 0.89
Relationship between mutations in the DNA gyrase and topoisomerase IV genes and nadifloxacin resistance in clinically isolated quinolone-resistant Staphylococcus aureus. J Infect Chemother (2001) 0.87
Interplay between intrinsic and acquired resistance to quinolones in Stenotrophomonas maltophilia. Environ Microbiol (2014) 0.87
Detection of the Smqnr quinolone protection gene and its prevalence in clinical isolates of Stenotrophomonas maltophilia in China. J Med Microbiol (2011) 0.86
In vitro activity of ciprofloxacin, levofloxacin, and trovafloxacin, alone and in combination with beta-lactams, against clinical isolates of Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Burkholderia cepacia. Diagn Microbiol Infect Dis (1999) 0.83
Efflux pump-mediated resistance in chemotherapy. Ann Med Health Sci Res (2012) 0.83
Comparative activities of six different fluoroquinolones against 9,682 clinical bacterial isolates from 20 European university hospitals participating in the European SENTRY surveillance programme. The SENTRY participants group. Int J Antimicrob Agents (1999) 0.82
Prevalence of plasmid-mediated quinolone resistance determinants among oxyiminocephalosporin-resistant Enterobacteriaceae in Argentina. Mem Inst Oswaldo Cruz (2013) 0.81
Antimicrobial susceptibility of enterococci in vitro. J Formos Med Assoc (1993) 0.80
In vitro activity of newer fluoroquinolones against Stenotrophomonas maltophilia. J Antimicrob Chemother (2000) 0.78
Clinical factors associated with acquisition of resistance to levofloxacin in Stenotrophomonas maltophilia. Yonsei Med J (2014) 0.77
Emergence of plasmid-mediated quinolone resistance genes in clinical isolates of Acinetobacter baumannii and Pseudomonas aeruginosa in Henan, China. Diagn Microbiol Infect Dis (2014) 0.77
Topoisomerases mutations and fluoroquinolone resistance in Stenotrophomonas maltophilia. Int J Antimicrob Agents (2004) 0.76
Bacteremia caused by Stenotrophomonas maltophilia in a dialysis patient with a long-term central venous catheter. Infect Control Hosp Epidemiol (2006) 0.76
DNA gyrase and topoisomerase IV mutations in an in vitro fluoroquinolone-resistant Coxiella burnetii strain. Microb Drug Resist (2010) 0.76